Juvenile myelomonocytic leukemia relapsing after allogeneic bone marrow transplantation successfully treated with interferon-alpha.

Abstract

We report a 5-year-old boy with juvenile myelomonocytic leukemia (JMML) which relapsed after an allogeneic bone marrow transplant who was successfully treated with interferon-alpha (IFN-alpha). One year after starting the therapy, he remains clinically well and in complete remission while continuing treatment with IFN-alpha and bestatin. Although the precise mechanism by which remission was induced is uncertain, a GVL effect combined with a direct antileukemia effect of IFN-alpha may be responsible. Further assessment of the role of IFN-alpha in relapsed JMLL patients is warranted.

• Authors: H Ohta, M Kawai, A Sawada, S Tokimasa, H Fujisaki, Y Matsuda, Y Osugi, S Okada, J Hara
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 26 Issue 6 Pg. 681-3 (Sep 2000) ISSN: 0268-3369 [Print] England
• PMID: 11041570 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Interferon-alpha

Topics

• Antineoplastic Agents (therapeutic use)
• Bone Marrow Transplantation
• Child, Preschool
• Combined Modality Therapy
• Graft vs Leukemia Effect
• Humans
• Interferon-alpha (therapeutic use)
• Leukemia, Myelomonocytic, Chronic (drug therapy, therapy)
• Male